Discussions on expanding coverage of the one-shot gene therapy ‘Luxturna’ is not making much progress.

Therefore, the industry’s eyes are on whether Novartis Korea’s Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) will be presented as an agenda for deliberation by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee within this year.

Novartis Korea applied for reimbursement of the drug in September last year, but no news has been heard on its passage of the Drug Reimbursement Standard Subcommittee until now. However, based on the speed of progress, the drug can still be listed in the first half of next year at the